Posted by Michael Wonder on 30 Dec 2020
Novo Nordisk files for EU regulatory approval of once weekly semaglutide 2 mg for the treatment of type 2 diabetes mellitus
29 December 2020 - Novo Nordisk today announced the submission of a label extension application to the EMA for the existing marketing authorisation for Ozempic, a once weekly glucagon-like peptide-1 analogue, to introduce a new dose of 2 mg.
Ozempic is currently approved in the EU in 0.5 mg and 1 mg doses for the treatment of type 2 diabetes mellitus in adults.
